Moving forward in bladder cancer detection and diagnosis: The role of epigenetic biomarkers

Expert Review of Molecular Diagnostics

Volumn 12, Issue 8, 2012, Pages 871-878

  Oliveira, Ana Isabel ^a   Jerónimo, Carmen ^a,b   Henrique, Rui ^a,b  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

bladder cancer; DNA methylation; epigenetic based biomarkers; histone modifications; miRNAs; molecular diagnosis; oncology

Indexed keywords

DEATH ASSOCIATED PROTEIN KINASE; G PROTEIN COUPLED RECEPTOR 54; GLUTATHIONE TRANSFERASE P1; GROWTH DIFFERENTIATION FACTOR 15; HISTONE H2AX; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MYOPODIN; PROTEIN BCL 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSCRIPTION FACTOR GATA 2; TRANSCRIPTION FACTOR HOXA9; TRANSCRIPTION FACTOR POU4F2; TRANSCRIPTION FACTOR SOX9; TRANSCRIPTION FACTOR T BET; TRANSCRIPTION FACTOR TWIST; TUMOR MARKER; UNCLASSIFIED DRUG;

APOPTOSIS; BLADDER CANCER; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CYSTOSCOPY; DISEASE SEVERITY; DNA METHYLATION; DNA MICROARRAY; EPIGENETICS; HUMAN; NON INVASIVE PROCEDURE; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; REVIEW; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; TUMOR GROWTH; URINE CYTOLOGY;

EARLY DETECTION OF CANCER; EPIGENESIS, GENETIC; EPIGENOMICS; HUMANS; PATHOLOGY, MOLECULAR; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84871301018     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.12.114     Document Type: Review

References (69)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA. Cancer J. Clin. 62(1), 10-29 (2012).
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127(12), 2893-2917 (2010).
3. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 374(9685), 239-249 (2009).
4. Shariat SF, Sfakianos JP, Droller MJ, Karakiewicz PI, Meryn S, Bochner BH. The effect of age and gender on bladder cancer: a critical review of the literature. BJU Int. 105(3), 300-308 (2010).
5. Mitra AP, Cote RJ. Molecular pathogenesis and diagnostics of bladder cancer. Annu. Rev. Pathol. 4, 251-285 (2009).
6. Bolenz C, Lotan Y. Molecular biomarkers for urothelial carcinoma of the bladder: challenges in clinical use. Nat. Clin. Pract. Urol. 5(12), 676-685 (2008).
7. Cordon-Cardo C. Molecular alterations associated with bladder cancer initiation and progression. Scand. J. Urol. Nephrol. Suppl. 218, 154-165 (2008).
8. Cheng L, Zhang S, MacLennan GT, Williamson SR, Lopez-Beltran A, Montironi R. Bladder cancer: translating molecular genetic insights into clinical practice. Hum. Pathol. 42(4), 455-481 (2011).
9. Sharma S, Ksheersagar P, Sharma P. Diagnosis and treatment of bladder cancer. Am. Fam. Physician 80(7), 717-723 (2009).
10. Knowles MA. Molecular pathogenesis of bladder cancer. Int. J. Clin. Oncol. 13(4), 287-297 (2008).
11. Rodríguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat. Med. 17(3), 330-339 (2011).
12. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 31(1), 27-36 (2010).
13. Mulero-Navarro S, Esteller M. Epigenetic biomarkers for human cancer: the time is now. Crit. Rev. Oncol. Hematol. 68(1), 1-11 (2008).
14. Füllgrabe J, Kavanagh E, Joseph B. Histone onco-modifications. Oncogene 30(31), 3391-3403 (2011).
15. Di Leva G, Croce CM. Roles of small RNAs in tumor formation. Trends Mol. Med. 16(6), 257-267 (2010).
16. Dudziec E, Goepel JR, Catto JW. Global epigenetic profiling in bladder cancer. Epigenomics 3(1), 35-45 (2011).
17. Enokida H, Nakagawa M. Epigenetics in bladder cancer. Int. J. Clin. Oncol. 13(4), 298-307 (2008).
18. Jeronimo C, Henrique R. Epigenetic biomarkers in urological tumors: a systematic review. Cancer Lett. doi:10.1016/j.canlet.2011.12.026 (2011) (Epub ahead of print).
19. Kim WJ, Kim YJ. Epigenetic biomarkers in urothelial bladder cancer. Expert Rev. Mol. Diagn. 9(3), 259-269 (2009).
20. Phé V, Cussenot O, Rouprêt M. Interest of methylated genes as biomarkers in urothelial cell carcinomas of the urinary tract. BJU Int. 104(7), 896-901 (2009).
21. Sánchez-Carbayo M. Hypermethylation in bladder cancer: biological pathways and translational applications. Tumour Biol. 33(2), 347-361 (2012).
22. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet. 8(4), 286-298 (2007).
23. Schones DE, Zhao K. Genome-wide approaches to studying chromatin modifications. Nat. Rev. Genet. 9(3), 179-191 (2008).
24. Harrison A, Parle-McDermott A. DNA methylation: a timeline of methods and applications. Front. Genet. 2, 74 (2011).
25. Beck S, Rakyan VK. The methylome: approaches for global DNA methylation profiling. Trends Genet. 24(5), 231-237 (2008).
26. Aleman A, Adrien L, Lopez-Serra L et al. Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays. Br. J. Cancer 98(2), 466-473 (2008).
27. Costa VL, Henrique R, Danielsen SA et al. Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. Clin. Cancer Res. 16(23), 5842-5851 (2010).
28. Dyrskjøt L, Ostenfeld MS, Bramsen JB et al. Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res. 69(11), 4851-4860 (2009).
29. Reinert T, Modin C, Castano FM et al. Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers. Clin. Cancer Res. 17(17), 5582-5592 (2011).
30. Shirodkar SP, Lokeshwar VB. Potential new urinary markers in the early detection of bladder cancer. Curr. Opin. Urol. 19(5), 488-493 (2009).
31. Chan MW, Chan LW, Tang NL et al. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin. Cancer Res. 8(2), 464-470 (2002).
32. Dulaimi E, Uzzo RG, Greenberg RE, Al-Saleem T, Cairns P. Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin. Cancer Res. 10(6), 1887-1893 (2004).
33. Friedrich MG, Weisenberger DJ, Cheng JC et al. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin. Cancer Res. 10(22), 7457-7465 (2004).
34. Hoque MO, Begum S, Topaloglu O et al. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J. Natl Cancer Inst. 98(14), 996-1004 (2006).
35. Renard I, Joniau S, van Cleynenbreugel B et al. Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples. Eur. Urol. 58(1), 96-104 (2010).
36. Serizawa RR, Ralfkiaer U, Dahl C et al. Custom-designed MLPA using multiple short synthetic probes: application to methylation analysis of five promoter CpG islands in tumor and urine specimens from patients with bladder cancer. J. Mol. Diagn. 12(4), 402-408 (2010).
37. Cabello MJ, Grau L, Franco N et al. Multiplexed methylation profiles of tumor suppressor genes in bladder cancer. J. Mol. Diagn. 13(1), 29-40 (2011).
38. Raman JD, Mongan NP, Tickoo SK, Boorjian SA, Scherr DS, Gudas LJ. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clin. Cancer Res. 11(24 Pt 1), 8570-8576 (2005).
39. Hayami S, Kelly JD, Cho HS et al. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int. J. Cancer 128(3), 574-586 (2011).
40. Kauffman EC, Robinson BD, Downes MJ et al. Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer. Mol. Carcinog. 50(12), 931-944 (2011).
41. Hanke M, Hoefig K, Merz H et al. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol. Oncol. 28(6), 655-661 (2010).
42. Puerta-Gil P, García-Baquero R, Jia AY et al. miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer. Am. J. Pathol. 180(5), 1808-1815 (2012).
43. Dudziec E, Miah S, Choudhry HM et al. Hypermethylation of CpG islands and shores around specific microRNAs and mirtrons is associated with the phenotype and presence of bladder cancer. Clin. Cancer Res. 17(6), 1287-1296 (2011).
44. Catto JW, Miah S, Owen HC et al. Distinct microRNA alterations characterize high-and low-grade bladder cancer. Cancer Res. 69(21), 8472-8481 (2009).
45. Ellinger J, El Kassem N, Heukamp LC et al. Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer. J. Urol. 179(1), 346-352 (2008).
46. Marsit CJ, Karagas MR, Danaee H et al. Carcinogen exposure and gene promoter hypermethylation in bladder cancer. Carcinogenesis 27(1), 112-116 (2006).
47. Aleman A, Cebrian V, Alvarez M et al. Identification of PMF1 methylation in association with bladder cancer progression. Clin. Cancer Res. 14(24), 8236-8243 (2008).
48. Cebrian V, Fierro M, Orenes-Pinero E et al. KISS1 methylation and expression as tumor stratification biomarkers and clinical outcome prognosticators for bladder cancer patients. Am. J. Pathol. 179(2), 540-546 (2011).
49. Cebrian V, Alvarez M, Aleman A et al. Discovery of myopodin methylation in bladder cancer. J. Pathol. 216(1), 111-119 (2008).
50. Tada Y, Wada M, Taguchi K et al. The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers. Cancer Res. 62(14), 4048-4053 (2002).
51. Sathyanarayana UG, Maruyama R, Padar A et al. Molecular detection of noninvasive and invasive bladder tumor tissues and exfoliated cells by aberrant promoter methylation of laminin-5 encoding genes. Cancer Res. 64(4), 1425-1430 (2004).
52. Duarte-Pereira S, Paiva F, Costa VL et al. Prognostic value of opioid binding protein/cell adhesion molecule-like promoter methylation in bladder carcinoma. Eur. J. Cancer 47(7), 1106-1114 (2011).
53. Marsit CJ, Karagas MR, Andrew A et al. Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer. Cancer Res. 65(16), 7081-7085 (2005).
54. Yates DR, Rehman I, Abbod MF et al. Promoter hypermethylation identifies progression risk in bladder cancer. Clin. Cancer Res. 13(7), 2046-2053 (2007).
55. Catto JW, Azzouzi AR, Rehman I et al. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J. Clin. Oncol. 23(13), 2903-2910 (2005).
56. Friedrich MG, Chandrasoma S, Siegmund KD et al. Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma. Eur. J. Cancer 41(17), 2769-2778 (2005).
57. Marsit CJ, Houseman EA, Christensen BC et al. Identification of methylated genes associated with aggressive bladder cancer. PLoS ONE 5(8), e12334 (2010).
58. Kandimalla R, van Tilborg AA, Kompier LC et al. Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers. Eur. Urol. 61(6), 1245-1256 (2012).
59. Agundez M, Grau L, Palou J, Algaba F, Villavicencio H, Sanchez-Carbayo M. Evaluation of the methylation status of tumour suppressor genes for predicting bacillus Calmette-Guérin response in patients with T1G3 high-risk bladder tumours. Eur. Urol. 60(1), 131-140 (2011).
60. Alvarez-Mugica M, Cebrian V, Fernández-Gomez JM, Fresno F, Escaf S, Sánchez-Carbayo M. Myopodin methylation is associated with clinical outcome in patients with T1G3 bladder cancer. J. Urol. 184(4), 1507-1513 (2010).
61. Wolff EM, Chihara Y, Pan F et al. Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue. Cancer Res. 70(20), 8169-8178 (2010).
62. Cheung WL, Albadine R, Chan T, Sharma R, Netto GJ. Phosphorylated H2AX in noninvasive low grade urothelial carcinoma of the bladder: correlation with tumor recurrence. J. Urol. 181(3), 1387-1392 (2009).
63. Barbisan F, Mazzucchelli R, Santinelli A et al. Immunohistochemical evaluation of global DNA methylation and histone acetylation in papillary urothelial neoplasm of low malignant potential. Int. J. Immunopathol. Pharmacol. 21(3), 615-623 (2008).
64. Schneider AC, Heukamp LC, Rogenhofer S et al. Global histone H4K20 trimethylation predicts cancer-specific survival in patients with muscle-invasive bladder cancer. BJU Int. 108(8 Pt 2), E290-E296 (2011).
65. Vallot C, Stransky N, Bernard-Pierrot I et al. A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression. J. Natl Cancer Inst. 103(1), 47-60 (2011).
66. Wang H, Albadine R, Magheli A et al. Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder. Urol. Oncol. 30(4), 428-433 (2012).
67. Hinz S, Kempkensteffen C, Christoph F et al. Expression of the polycomb group protein EZH2 and its relation to outcome in patients with urothelial carcinoma of the bladder. J. Cancer Res. Clin. Oncol. 134(3), 331-336 (2008).
68. Veerla S, Lindgren D, Kvist A et al. MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. Int. J. Cancer 124(9), 2236-2242 (2009).
69. Wiklund ED, Bramsen JB, Hulf T et al. Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int. J. Cancer 128(6), 1327-1334 (2011).